Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diovol is a combination antacid and antiflatulent medication developed and marketed by Wallace Laboratories (Wallace Pharmaceuticals). It is formulated to provide rapid and long-lasting relief from symptoms of hyperacidity, heartburn, acid indigestion, gastritis, and flatulence (gas). The medication typically contains a combination of active ingredients, including aluminium hydroxide and magnesium hydroxide, which act as antacids to neutralize excess stomach acid, and dimethicone (or simethicone), which acts as an antiflatulent to break down trapped gas bubbles in the gastrointestinal tract. Diovol is available in various oral dosage forms, including suspensions and chewable tablets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Diovol.